Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden

Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden
About 43% of Fisher & Paykel Healthcare’s revenue comes from the US. (Image: Supplied)
John Anthony
Jarden has raised its rating and target share price for Fisher & Paykel Healthcare by 10%, as Thursday’s US tariff announcements proved less damaging than expected.Following US President Donald Trump’s unveiling of “Liberation Day” tariffs, shares in Fisher & Paykel Healthcare (FPH), a company with significant export exposure to the US, traded as low as $32.60 in the wake of the announcement on Thursday. They were currently at $34.80.In a research note released late Thursday evening, Jarden analysts Adrian Allbon...

More Economy

RBNZ 25bps rate cut wasn't unanimous
Economy

RBNZ 25bps rate cut wasn't unanimous

The vote was 5 to 1 to cut by 25 basis points. 

Rebecca Howard 28 May 2025
RBNZ cuts, signals more to come
Economy

RBNZ cuts, signals more to come

Risks around the economic outlook are heightened. 

Rebecca Howard 28 May 2025
Not everyone thinks the RBNZ should cut this week
Economy

Not everyone thinks the RBNZ should cut this week

Three out of five members of NZIER's Shadow Board recommend a hold. 

Rebecca Howard 26 May 2025
RBNZ rate cut baked in, eyes on track
Economy

RBNZ rate cut baked in, eyes on track

The RBNZ is expected to cut by 25 basis points to 3.25%.  

Rebecca Howard 26 May 2025